Active Ingredient History
Olaparib is an oral inhibitor of poly (ADP-ribose) polymerase enzymes, including PARP1, PARP2, and PARP3 which are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has shown activity in ovarian and breast tumors with known BRCA mutations and was the first FDA approved drug in this class. Lynparza (olaparib) is indicated for treatment of gBRCA-mutated advanced ovarian cancer. Its use together with other chemotherapy medicines can lead to increased effects on the blood resulting in reduction in the numbers of white blood cells and platelets, and anaemia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adnexal Diseases (Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Anemia (Phase 1)
Angiogenesis Modulating Agents (Phase 2)
Antineoplastic Agents (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 1)
BRCA1 Protein (Phase 3)
BRCA2 Protein (Phase 1)
Breast (Phase 2)
Breast Neoplasms (Phase 4)
Carboplatin (Phase 1)
Carcinoma (Phase 2)
Carcinoma, Endometrioid (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 4)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Carcinosarcoma (Phase 2)
Cholangiocarcinoma (Phase 2)
Clinical Trial, Phase I (Phase 1)
Colorectal Neoplasms (Phase 3)
Cytoreduction Surgical Procedures (Phase 2)
DNA Repair-Deficiency Disorders (Phase 2)
Drugs, Investigational (Phase 2)
Endometrial Neoplasms (Phase 4)
Ependymoma (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Genital Diseases, Female (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 1)
Hepatoblastoma (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 1/Phase 2)
Homologous Recombination (Phase 2)
Hypotension (Phase 2)
Immunotherapy (Phase 2)
Inflammatory Breast Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Laryngeal Neoplasms (Phase 1)
Leiomyosarcoma (Phase 2/Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplasms by Histologic Type (Phase 2)
Neoplasms by Site (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Glandular and Epithelial (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Paclitaxel (Phase 1)
Pancreatic Diseases (Phase 2)
Pancreatic Neoplasms (Phase 3)
Peritoneal Neoplasms (Phase 3)
Pharmacological and Toxicological Phenomena (Phase 1/Phase 2)
Pheochromocytoma (Phase 2)
Platinum Compounds (Phase 3)
Poly(ADP-ribose) Polymerase Inhibitors (Phase 2)
Primary Myelofibrosis (Phase 1)
Prostate (Phase 2)
Prostatic Neoplasms (Phase 3)
PTEN Phosphohydrolase (Phase 2)
Pulmonary Arterial Hypertension (Phase 1)
Radiotherapy (Phase 1/Phase 2)
Recurrence (Phase 2)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Thymoma (Phase 1)
Thyroid Neoplasms (Phase 4)
Triple Negative Breast Neoplasms (Phase 2/Phase 3)
Urinary Bladder Neoplasms (Phase 2)
Urogenital Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
